• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Pliant Therapeutics, Inc. - Common Stock (NQ:PLRX)

    1.141 -0.019 (-1.68%)
    Streaming Delayed Price Updated: 10:11 AM EDT, Aug 27, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 20,798
    Open 1.160
    Bid (Size) 1.140 (4,300)
    Ask (Size) 1.150 (2,600)
    Prev. Close 1.160
    Today's Range 1.141 - 1.160
    52wk Range 1.020 - 1.950
    Shares Outstanding 35,937,937
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -8.8%
    -8.8%
    1 Month
    +5.6%
    +5.6%
    3 Month
    -8.0%
    -8.0%
    6 Month
    -10.9%
    -10.9%
    1 Year
    -29.6%
    -29.6%

    More News

    Read More
    News headline image
    Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    United Therapeutics Surges 14% on Groundbreaking Tyvaso Phase 3 Results for IPF
    Via MarketMinute
    News headline image
    Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Keep an eye on the top gainers and losers in Thursday's session. ↗
    Via Chartmill
    News headline image
    Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Friday's After-Market Session ↗
    Via Benzinga
    News headline image
    Get insights into the top gainers and losers of Friday's after-hours session. ↗
    Via Chartmill
    News headline image
    Pliant Therapeutics Provides Update on BEACON-IPF
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. – PLRX
    From Pomerantz LLP
    Via GlobeNewswire

    Frequently Asked Questions

    Is Pliant Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Pliant Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Pliant Therapeutics, Inc. - Common Stock trade on?
    Pliant Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Pliant Therapeutics, Inc. - Common Stock?
    The ticker symbol for Pliant Therapeutics, Inc. - Common Stock is PLRX on the Nasdaq Stock Market
    What is the current price of Pliant Therapeutics, Inc. - Common Stock?
    The current price of Pliant Therapeutics, Inc. - Common Stock is 1.141
    When was Pliant Therapeutics, Inc. - Common Stock last traded?
    The last trade of Pliant Therapeutics, Inc. - Common Stock was at 08/27/26 10:11 AM ET
    What is the market capitalization of Pliant Therapeutics, Inc. - Common Stock?
    The market capitalization of Pliant Therapeutics, Inc. - Common Stock is 40.99M
    How many shares of Pliant Therapeutics, Inc. - Common Stock are outstanding?
    Pliant Therapeutics, Inc. - Common Stock has 41M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.